RCTs specifically designed to evaluate HF outcomes are essential to clarify whether PPARα agonists can complement established neurohormonal treatments, particularly in the context of the rising burden of HFpEF associated with obesity and type 2 diabetes. This evidence concerns the gene PPARA and obesity due to melanocortin 4 receptor deficiency.